Vertex Pharmaceuticals Gets Expanded FDA Approval for Trikafta

MT Newswires Live12-21 04:59

Vertex Pharmaceuticals (VRTX) said Friday that the US Food and Drug Administration granted expanded approval for Trikafta to children ages 2 or older with cystic fibrosis and certain of its genetic profiles.

The approval covers patients who have at least one F508del mutation or another mutation that responds to Trikafta, according to the company.

The FDA also updated safety information related to liver injury and liver failure to a boxed warning.

Vertex said the approval extends Trikafta's label with 94 new non-F508del cystic fibrosis transmembrane conductance regulator mutations.

Price: 397.56, Change: +0.92, Percent Change: +0.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment